Biomarkers of Oxidative Damage and Inflammation in Alzheimer's Disease

• Markesbery WR : Oxidative stress hypothesis in Alzheimer's disease.Free Radic. Biol. Med.23, 134–147 (1997).
   PubMed Web of Science ®Google Scholar
• Perry G , NunomuraA, HiraiK et al.: Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases?Free Radic. Biol. Med.33, 1475–1479 (2002).
   PubMed Web of Science ®Google Scholar
• Golden TR , HinerfeldDA, MelovS: Oxidative stress and aging: beyond correlation.Aging Cell1, 117–123 (2002).
   PubMed Web of Science ®Google Scholar
• Keller JN , SchmittFA, ScheffSW et al.: Evidence of increased oxidative damage in subjects with mild cognitive impairment.Neurology64, 1152–1156 (2005).
   PubMed Web of Science ®Google Scholar
• Schwab C , McGeerPL: Inflammatory aspects of Alzheimer disease and other neurodegenerative disorders.J. Alzheimers Dis.13, 359–369 (2008).
   PubMed Web of Science ®Google Scholar
• Rozemuller AJ , van GoolWA, EikelenboomP: The neuroinflammatory response in plaques and amyloid angiopathy in Alzheimer's disease: therapeutic implications. Curr. Drug Targets CNS Neurol. Disord.4, 223–233 (2005).
   PubMedGoogle Scholar
• Lucin KM , Wyss-CorayT: Immune activation in brain aging and neurodegeneration: too much or too little?Neuron64, 110–122 (2009).
   PubMed Web of Science ®Google Scholar
• Bertram L , TanziRE: Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses.Nat. Rev. Neurosci.9, 768–778 (2008).
   PubMed Web of Science ®Google Scholar
• Lambert JC , HeathS, EvenG et al.: Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease.Nat. Genet.41, 1094–1099 (2009).
   PubMed Web of Science ®Google Scholar
• Harold D , AbrahamR, HollingworthP et al.: Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease.Nat. Genet.41, 1088–1093 (2009).
   PubMed Web of Science ®Google Scholar
• Kim J , BasakJM, HoltzmanDM: The role of apolipoprotein E in Alzheimer's disease.Neuron63, 287–303 (2009).
   PubMed Web of Science ®Google Scholar
• Kadiiska MB , GladenBC, BairdDD et al.: Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning?Free Radic. Biol. Med.38, 698–710 (2005).
   PubMed Web of Science ®Google Scholar
• Vanderstichele H , Van KerschaverE, HesseCet al.: Standardization of measurement of β-amyloid1–42 in cerebrospinal fluid and plasma. Amyloid 7, 245–258 (2000).
   PubMed Web of Science ®Google Scholar
• Abe T , TohgiH, IsobeC, MurataT, SatoC: Remarkable increase in the concentration of 8-hydroxyguanosine in cerebrospinal fluid from patients with Alzheimer's disease.J. Neurosci. Res.70, 447–450 (2002).
   PubMed Web of Science ®Google Scholar
• Montine TJ , QuinnJ, KayeJ, MorrowJD: F2-isoprostanes as biomarkers of late-onset Alzheimer's disease.J. Mol. Neurosci.33, 114–119 (2007).
   PubMed Web of Science ®Google Scholar
• Praticò D , UryuK, LeightS, TrojanoswkiJQ, LeeVM: Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis.J. Neurosci.21, 4183–4187 (2001).
   PubMed Web of Science ®Google Scholar
• Yao Y , ZhukarevaV, SungS et al.: Enhanced brain levels of 8,12-iso-iPF2α-VI differentiate AD from frontotemporal dementia.Neurology61, 475–478 (2003).
   PubMed Web of Science ®Google Scholar
• Montine TJ , BealMF, CudkowiczME et al.: Increased cerebrospinal fluid F2-IsoProstane concentration in probable Alzheimer's disease.Neurology52, 562–565 (1999).
   PubMed Web of Science ®Google Scholar
• Pratico D , ClarkCM, LeeVMY, TrojanowskiJQ, RokachJ, FitzgeraldG: Increased 8,12-iso-iPF2α-IV in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity.Ann. Neurol.48, 809–812 (2000).
   PubMed Web of Science ®Google Scholar
• Montine TJ , KayeJA, MontineKS, McFarlandL, MorrowJD, QuinnJF: CSF Aβ42, tau, and F2-IsoProstane concentrations in patients with Alzheimer's disease, other dementias, and age-matched controls.Arch. Pathol. Lab. Med.125, 510–512 (2001).
   PubMed Web of Science ®Google Scholar
• Pratico D , ClarkCM, LiunF, RokachJ, LeeVY, TrojanowskiJQ: Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease.Arch. Neurol.59, 972–976 (2002).
   PubMedGoogle Scholar
• de Leon MJ , MosconiL, LiJ et al.: Longitudinal CSF isoprostane and MRI atrophy in the progression to AD.J. Neurol.254, 1666–1675 (2007).
   PubMed Web of Science ®Google Scholar
• Ringman JM , YounkinSG, PraticoD et al.: Biochemical markers in persons with preclinical familial Alzheimer disease.Neurology71, 85–92 (2008).
   PubMed Web of Science ®Google Scholar
• Montine TJ , QuinnJF, MilatovicD et al.: Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease,Ann. Neurol.52, 175–179 (2002).
   PubMed Web of Science ®Google Scholar
• Irizarry MC , YaoY, HymanBT, GrowdonJH, PraticòD: Plasma F2A isoprostane levels in Alzheimer's and Parkinson's disease.Neurodegener. Dis.4, 403–405 (2007).
   PubMed Web of Science ®Google Scholar
• Quinn JF , MontineKS, MooreM, MorrowJD, KayeJA, MontineTJ: Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease.J. Alzheimers Dis.6, 93–97 (2004).
   PubMed Web of Science ®Google Scholar
• Pirttila T , MehtaPD, FreyH, WisniewskiHM: α1-antichymotrypsin and IL-1β are not increased in CSF or serum in Alzheimer's disease.Neurobiol. Aging15, 313–317 (1994).
   PubMedGoogle Scholar
• Teunissen CE , de VenteJ, SteinbuschHW, De BruijnC: Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol. Aging23, 485–508 (2002).
   PubMed Web of Science ®Google Scholar
• DeKosky ST , IkonomovicMD, WangX et al.: Plasma and cerebrospinal fluid α1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment.Ann. Neurol.53, 81–90 (2003).
   PubMed Web of Science ®Google Scholar
• Gonçalves CA , LeiteMC, NardinP: Biological and methodological features of the measurement of s100B, a putative marker of brain injury.Clin. Biochem.41, 755–763 (2008).
   PubMed Web of Science ®Google Scholar
• Peskind ER , GriffinWS, AkamaKT, RaskindMA, Van EldikLJ: Cerebrospinal fluid s100B is elevated in the earlier stages of Alzheimer's disease. Neurochem. Int.39, 409–413 (2001).
   PubMed Web of Science ®Google Scholar
• Petzold A , JenkinsR, WattHC et al.: Cerebrospinal fluid s100B correlates with brain atrophy in Alzheimer's disease.Neurosci. Lett.336, 167–170 (2003).
   PubMed Web of Science ®Google Scholar
• Rosengren LE , Wikkels⊘C, HagbergL: A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adults.Neurosci. Methods51, 197–204 (1994).
   PubMed Web of Science ®Google Scholar
• Jesse S , SteinackerP, CepekL et al.: Glial fibrillary acidic protein and protein S-100B: different concentration pattern of glial proteins in cerebrospinal fluid of patients with Alzheimer's Disease and Creutzfeldt-Jakob disease.J. Alzheimers Dis.5(4 Suppl. 1) , 505–506 (2009).
   Google Scholar
• Tarkowski E , BlennowK, WallinA, TarkowskiA: Intracerebral production of tumor necrosis factor-α, a local neuroprotective agent, in Alzheimer disease and vascular dementia.J. Clin. Immunol.19, 223–230 (1999).
   PubMed Web of Science ®Google Scholar
• Tarkowski E , AndreasenN, TarkowskiA, BlennowK: Intrathecal inflammation precedes development of Alzheimer's disease.J. Neurol. Neurosurg. Psychiatr.74, 1200–1205 (2003).
   PubMed Web of Science ®Google Scholar
• Garlind A , BraunerA, HöjebergB, BasunH, SchultzbergM: Soluble interleukin-1 receptor type II levels are elevated in cerebrospinal fluid in Alzheimer's disease patients.Brain Res.826, 112–116 (1999).
   PubMed Web of Science ®Google Scholar
• Blasko I , LedererW, OberbauerH et al.: Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias.Dement. Geriatr. Cogn. Disord.21, 9–15 (2006).
   PubMed Web of Science ®Google Scholar
• Lindberg C , ChromekM, AhrengartL, BraunerA, SchultzbergM, GarlindA: Soluble interleukin-1 receptor type II, IL-18 and caspase-1 in mild cognitive impairment and severe Alzheimer's disease.Neurochem. Int.46, 551–557 (2005).
   PubMed Web of Science ®Google Scholar
• Popp J , BacherM, KölschH et al.: Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease.J. Psychiatr. Res.43, 749–753 (2009).
   PubMed Web of Science ®Google Scholar
• van Exel E , EikelenboomP, ComijsH et al.: Vascular factors and markers of inflammation in offspring with a parental history of late-onset Alzheimer disease.Arch. Gen. Psychiatry66, 1263–1270 (2009).
   PubMed Web of Science ®Google Scholar
• Sun YX , MinthonL, WallmarkA, WarkentinS, BlennowK, JanciauskieneS: Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer's disease.Dement. Geriatr. Cogn. Disord.16, 136–144 (2003).
   PubMed Web of Science ®Google Scholar
• Galimberti D , SchoonenboomN, ScheltensP et al.: Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease.Arch. Neurol.63, 538–543 (2006).
   PubMedGoogle Scholar
• Choi C , JeongJH, JangJS et al.: Multiplex analysis of cytokines in the serum and cerebrospinal fluid of patients with Alzheimer's disease by color-coded bead technology.J. Clin. Neurol.4, 84–88 (2008).
   PubMed Web of Science ®Google Scholar
• Nilselid AM , DavidssonP, NäggaK, AndreasenN, FredmanP, BlennowK: Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms.Neurochem. Int.48, 718–728 (2006).
   PubMed Web of Science ®Google Scholar
• Freund-Levi Y , HjorthE, LindbergC et al.: Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study.Dement. Geriatr. Cogn. Disord.27, 481–490 (2009).
   PubMed Web of Science ®Google Scholar
• Engelhart MJ , GeerlingsMI, MeijerJ et al.: Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study.Arch. Neurol.61, 668–672 (2004).
   PubMed Web of Science ®Google Scholar
• Tan ZS , BeiserAS, VasanRS et al.: Inflammatory markers and the risk of Alzheimer disease: the Framingham Study.Neurology68, 1902–1908 (2007).
   PubMed Web of Science ®Google Scholar
• Roberts RO , GedaYE, KnopmanDS et al.: Association of C-reactive protein with mild cognitive impairment.Alzheimers Dement.5, 398–405 (2009).
   PubMed Web of Science ®Google Scholar
• Holmes C , CunninghamC, ZotovaE et al.: Systemic inflammation and disease progression in Alzheimer disease.Neurology73, 768–774 (2009).
   PubMed Web of Science ®Google Scholar
• Ray S , BritschgiM, HerbertC et al.: Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins.Nat. Med.13, 1359–1362 (2007).
   PubMed Web of Science ®Google Scholar
• Blum-Degen D , MüllerT, KuhnW, GerlachM, PrzuntekH, RiedererP: Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.Neurosci. Lett.202, 17–20 (1995).
   PubMed Web of Science ®Google Scholar
• Galimberti D , VenturelliE, FenoglioC et al.: Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration.J. Neurol.255, 539–544 (2008).
   PubMed Web of Science ®Google Scholar
• Gómez-Tortosa E , GonzaloI, FanjulS et al.: Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.Arch. Neurol.60, 1218–1222 (2003).
   PubMedGoogle Scholar
• Hampel H , SchoenD, SchwarzMJ et al.: Interleukin-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer's disease.Neurosci. Lett.228, 143–146 (1997).
   PubMed Web of Science ®Google Scholar
• Tarkowski E , WallinA, ReglandB, BlennowK, TarkowskiA: Local and systemic GM-CSF increase in Alzheimer's disease and vascular dementia.Acta Neurol. Scand.103, 166–174 (2001).
   PubMed Web of Science ®Google Scholar
• Rota E , BelloneG, RoccaP, BergamascoB, EmanuelliG, FerreroP: Increased intrathecal TGF-β1, but not IL-12, IFN-γ and IL-10 levels in Alzheimer's disease patients.Neurol. Sci.27, 33–39 (2006).
   PubMed Web of Science ®Google Scholar
• Zetterberg H , AndreasenN, BlennowK: Increased cerebrospinal fluid levels of transforming growth factor-β1 in Alzheimer's disease.Neurosci. Lett.367, 194–196 (2004).
   PubMed Web of Science ®Google Scholar
• Tarkowski E , IssaR, SjögrenM et al.: Increased intrathecal levels of the angiogenic factors VEGF and TGF-β in Alzheimer's disease and vascular dementia.Neurobiol. Aging23, 237–243 (2002).
   PubMed Web of Science ®Google Scholar

Website

• Alzheimer's disease Neuroimaging Initative (ADNI) www.adni.org
   Google Scholar